Replies to post #4610 on Biotech Values

[biotplaya]

Hi Dew,

<At two months from baseline (one month from the end of treatment), 33% of Squalamine patients in the Mexican trial had improved vision, defined as a gain of 3+ lines (15 letters) relative to baseline. At four months from baseline (three months from the end of treatment), 26% of Squalamine patients in the Mexican trial still had improved vision, using the same definition>

my amateurish observation tells me 33% to 26% is not the way to go, especially when compared to Lucentis 45%,34%. Is there more to look at than this? Have you lost confidence in GENR to come through? Thank you.

[10nisman]

Dew,

What do you think of the following idea... Levitt and GENR are positioning Squalamine to be a monthly or bi-monthly nasal spray/pill that would be taken by all people starting at some age (say 30 and over) that will prevent future Wet AMD. If the 10mg has no long-term side effects, all people could take this monthly dosage and thus approx. no one would ever have to face Wet AMD. This market would seem to be massive relative to the current AMD market.

Also, based on all of your concerns why would institutional investors be willing to invest $13 million in GENR?

Let me know what you think.

Thanks,
10nis